Literature DB >> 1947797

Highly efficient expression of proteins encoded by recombinant vaccinia virus in lymphocytes.

J M Alonso1, J Rodriguez, E Viñuela, G Kroemer, C Martínez.   

Abstract

Using a recombinant vaccinia virus (VV) that expresses E. coli beta galactosidase (beta-Gal) to infect lymphocytes, we show that enzymometrically or immunologically detectable beta-Gal expression is less pronounced among T cells than among B cells. VV infection caused growth inhibition of B cells, but barely affected T-cell proliferation in vitro. Moreover, the production of infectious viral particles was less pronounced in T lymphocytes. Kinetic studies revealed that after an initial dose-dependent growth inhibition, T cells continued to proliferate without the doubling time being affected by VV infection. Nonetheless, the T cells do express proteins encoded by recombinant VV, such as beta-Gal, or secrete soluble proteins such as interleukin-4, though at a lower efficiency at the per cell level than B lymphocytes. In conclusion, the physiology of T cells appears to be less perturbed by VV than that of B cells, although the virus is capable of directing expression of recombinant genes to T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1947797     DOI: 10.1111/j.1365-3083.1991.tb01585.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

2.  Interactions between human immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex vivo.

Authors:  Christophe Vanpouille; Angélique Biancotto; Andrea Lisco; Beda Brichacek
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

3.  Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays.

Authors:  F D LaBrecque; D R LaBrecque; D Klinzman; S Perlman; J B Cederna; P L Winokur; J Q Han; J T Stapleton
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

4.  Susceptibility of different leukocyte cell types to Vaccinia virus infection.

Authors:  Juana M Sánchez-Puig; Laura Sánchez; Garbiñe Roy; Rafael Blasco
Journal:  Virol J       Date:  2004-11-22       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.